TX-MAVENIR
NEC Corporation (NEC), a leader in the integration of IT and network technologies, and Mavenir, the industry's only end-to-end cloud-native 4G/5G network software provider for Communication Service Providers (CSPs), have announced a collaboration to deliver a 5G Open virtualized RAN (vRAN) Solution to the Japanese Enterprise Market. This will open up Local/Private 5G Network opportunities for enterprises, regional authorities and other organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005085/en/
Under this collaboration, NEC and Mavenir will jointly work on 5G Open vRAN and Local 5G business developments and establish a simple and cost-efficient ecosystem in the market. The collaboration will bring together NEC’s expertise in IT, network and system integration and Mavenir’s field-proven cloud-native network technology.
Mavenir delivers an Open vRAN solution that provides strategic differentiation by enabling multisource Remote Radio Units (RRUs) to interwork with the virtualized, containerized, Cloud Base Band software over ethernet Fronthaul (FH), using the O-RAN open interface, overcoming the traditional constraints of the proprietary walled garden specifications used by the other traditional equipment vendors.
“We are excited to collaborate with NEC, as we move together toward open, virtualized networks,” said Pardeep Kohli, Mavenir’s President and CEO. “Mavenir’s vRAN and NEC’s radio naturally come together to quickly and easily bring new and innovative solutions to the Japanese Enterprise Market.”
NEC actively promotes an open, virtualized infrastructure model in support of the 5G era, utilizing IT, orchestration and network expertise. Moreover, the NEC ecosystem contributes to vRAN via interoperability testing between multiple vendors’ equipment that is compliant with O-RAN fronthaul specifications.
“The combination of advanced assets and expertise from Mavenir and NEC will enable us to offer end-to-end one-stop 5G Open vRAN and Local/Private 5G solutions, including an advanced 5G network solution for the ecosystem, and vertical solutions that meet the needs of a great variety of Enterprise customers,” said Nozomu Watanabe, senior vice president at NEC.
This joint collaboration will continue to provide value-added solutions for customers worldwide. An overview of this collaboration will be introduced during MWC Barcelona 2020 at the NEC booth, Hall 3, 3M30.
About Mavenir
Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE , VoWiFi , Advanced Messaging (RCS) , Multi-ID , vEPC and OpenRAN vRAN , Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve webscale economics, Mavenir offers solutions to help CSPs with revenue generation , cost reduction , and revenue protection . Learn more at www.mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc. |
Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved. |
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005085/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom